This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

ChinaBio™ Partnering Forum
April 28–29, 2026
Kerry Hotel Pudong, Shanghai, ChinaMay 6–7, 2026 - Digital Partnering

Albert Ren
VP, Head of Worldwide Business Development – China at Pfizer
Presenter

Profile

Dr. Albert Ren leads all search and evaluation activities focused on China for Global innovations (from candidate selections through preclinical and clinical assets), and support the transaction activities and enrich Pfizer Global development pipeline. His team continues to execute China for China BD opportunities (i.e., define strategy, search, evaluate, transact, manage alliance) to enrich Pfizer China portfolio and drive in-organic growth. In addition, Dr. Ren and his team strengthen Pfizer’s engagement and influence in China innovative eco-system, fostering strategic partnerships. Dr. Ren also takes on accountability for commercial development (i.e., new product planning) in China.

Dr. Ren has over 20 years of diverse experience in the biopharmaceutical industry, management consulting, and biotech. He was previously the Chief Strategy and Corporate Development Officer at Adagene, a NASDAQ-listed clinical stage biotech company. Dr. Ren and his team oversaw strategy, business development, portfolio prioritization, commercial assessment and valuation. Prior to joining Adagene, Dr. Ren worked at Merck & Company in a variety of capacities, including pipeline valuation lead in respiratory, immunology and infectious diseases. He was the finance and portfolio lead for oncology development, contributing to the development and commercialization of KEYTRUDA®. He worked in the Corporate Strategy Office on enterprise portfolio and business development strategies, as well as in Corporate BD on a variety of transactions.

Dr. Ren gained valuable business experience while working at McKinsey & Company and Quintiles/IQVIA Consulting. He worked on the development of growth strategies as well as the support of mergers and acquisitions in both the United States and China. Dr. Ren graduated from Peking University with a bachelor's degree in chemistry and a Ph.D. in chemistry from the University of Minnesota. He also attended McKinsey's Mini-MBA program

At this event